In this investing video, Owain Bennallack explains why he believes that AstraZeneca’s (LSE: AZN) (NYSE: AZN.US) statement that it expects to maintain 2013’s level of revenues to 2017 isn’t as downbeat as investors may initially think, and why both Astra and GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) are coming back into favour…
https://youtu.be/Ok0CMKHxoLs